234 related articles for article (PubMed ID: 26746857)
21. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
[TBL] [Abstract][Full Text] [Related]
22. [FGF-23 and Klotho protein - new markers in chronic kidney disease?].
Mituła I; Gołembiewska E; Ciechanowski K; Siuda A
Pol Merkur Lekarski; 2013 Apr; 34(202):235-8. PubMed ID: 23745333
[TBL] [Abstract][Full Text] [Related]
23. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
Evenepoel P; Rodriguez M; Ketteler M
Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
[TBL] [Abstract][Full Text] [Related]
24. Klotho in health and disease.
Kuro-o M
Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):362-8. PubMed ID: 22660551
[TBL] [Abstract][Full Text] [Related]
25. The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans.
Gołembiewska E; Stępniewska J; Kabat-Koperska J; Kędzierska K; Domański M; Ciechanowski K
Curr Protein Pept Sci; 2016; 17(8):821-826. PubMed ID: 27226196
[TBL] [Abstract][Full Text] [Related]
26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
27. FGF-23 in children with CKD: a new player in the development of CKD-mineral and bone disorder.
Siomou E; Stefanidis CJ
Nephrol Dial Transplant; 2012 Dec; 27(12):4259-62. PubMed ID: 22848110
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
Nitta K; Nagano N; Tsuchiya K
Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
[TBL] [Abstract][Full Text] [Related]
29. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
30. [A potential link between phosphate and aging].
Shiizaki K; Kuro-o M
Clin Calcium; 2012 Oct; 22(10):1493-8. PubMed ID: 23023628
[TBL] [Abstract][Full Text] [Related]
31. Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis.
Liu BH; Chong FL; Yuan CC; Liu YL; Yang HM; Wang WW; Fang QJ; Wu W; Wang MZ; Tu Y; Wan ZY; Wan YG; Wu GW
Front Pharmacol; 2020; 11():586725. PubMed ID: 33708111
[No Abstract] [Full Text] [Related]
32. Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease.
Nitta K
Int J Nephrol; 2010 Dec; 2010():167984. PubMed ID: 21234310
[TBL] [Abstract][Full Text] [Related]
33. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
34. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder.
Slatopolsky E
Kidney Int; 2011 Apr; 79121():S3-8. PubMed ID: 26746859
[TBL] [Abstract][Full Text] [Related]
35. FGF-23: More than a regulator of renal phosphate handling?
Jüppner H; Wolf M; Salusky IB
J Bone Miner Res; 2010 Oct; 25(10):2091-7. PubMed ID: 20593414
[TBL] [Abstract][Full Text] [Related]
36. FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan.
Balmukhanova A; Kabulbayev K; Alpay H; Kanatbayeva A; Balmukhanova A
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33379157
[No Abstract] [Full Text] [Related]
37. Serum soluble Klotho protein level is associated with residual diuresis in incident peritoneal dialysis patients.
Golembiewska E; Safranow K; Kabat-Koperska J; Myślak M; Ciechanowski K
Acta Biochim Pol; 2013; 60(2):191-4. PubMed ID: 23748218
[TBL] [Abstract][Full Text] [Related]
38. Phosphate is a vascular toxin.
Shroff R
Pediatr Nephrol; 2013 Apr; 28(4):583-93. PubMed ID: 23161206
[TBL] [Abstract][Full Text] [Related]
39. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
40. [Fibroblast growth factor-23 (FGF-23). Part I. Significance in phosphate homeostasis and bone metabolism].
Fedak D; Bigaj K; Sułowicz W
Przegl Lek; 2011; 68(4):231-8. PubMed ID: 21853680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
